Oesophageal cancer: does statin use help after diagnosis?

  • Cancer Epidemiol

  • from Antara Ghosh
  • Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Statin use may reduce oesophageal cancer-specific mortality after diagnosis, but the quality of evidence is low.

Why this matters

  • Evidence from cell lines and animal models suggest that statin has anti-tumour properties.
  • Statins inhibit proliferation and induce apoptosis in oesophageal adenocarcinoma cell lines which reveals their anti-tumour properties.

Study design

  • This cohort study evaluated 1921 patients diagnosed with oesophageal cancer between 2009 and 2012.
  • This study used a time varying covariate analysis, and the patients were considered at first as non-users and then after 6 mo as users.
  • Funding: None.

Key results

  • Mean follow-up duration was 2 y.
  • Statin use showed little evidence in the reduction of oesophageal cancer-specific mortality (adjusted HR, 0.93; 95% CI, 0.81-1.07) and dose-response association identified from the number of prescriptions.
  • Statin users showed a 12% reduction in the rate of oesophageal cancer-specific mortality before diagnosis (adjusted HR, 0.88; 95% CI, 0.79-0.99) vs statin non-users.
  • Association between statin and oesophageal cancer was seen when no lag (adjusted HR, 0.68; 95% CI, 0.61-0.76) or a 3-mo lag (adjusted HR, 0.80; 95% CI, 0.70-0.90) was used.

Limitations

  • Study had a lag of 6 mo.